Chatillon sur Chalaronne, France

Michel Cottin

This inventor holds 1 USPTO granted patent. Top assignee: Kali-Chemie Pharma Gmbh. Active years: 1994.


% Patents Active = 100.0

Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 11(Granted Patents)


Company Filing History:


Years Active: 1994

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Michel Cottin: Innovator in Pharmacological Compounds

Introduction

Michel Cottin is a notable inventor based in Chatillon sur Chalaronne, France. He has made significant contributions to the field of pharmacology, particularly in the development of compounds with anti-allergic properties. His work has led to the creation of innovative solutions that address important health issues.

Latest Patents

Cottin holds a patent for "7-fused 2-(piperazinoalkyl) indole derivatives, intermediates and pharmacologically active compounds having anti-allergic properties." This patent describes compounds that can be mono- or disubstituted in the phenyl ring, along with their acid addition salts and/or S-mono- or dioxides of sulfur-containing compounds. The processes and intermediates for their preparation are also detailed in the patent.

Career Highlights

Michel Cottin is associated with Kali-Chemie Pharma GmbH, where he continues to contribute to the advancement of pharmaceutical innovations. His expertise in the field has been instrumental in developing new therapeutic agents that can improve patient outcomes.

Collaborations

Cottin has worked alongside notable colleagues such as Dominique Paris and Francois Floc'h. Their collaborative efforts have further enhanced the research and development of pharmacological compounds.

Conclusion

Michel Cottin's work exemplifies the impact of innovative thinking in the pharmaceutical industry. His contributions to anti-allergic compounds highlight the importance of research and collaboration in advancing healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…